Management of Metastatic Pancreatic Adenocarcinoma
| Autor: | Eileen M. O'Reilly, Ahmad R. Cheema |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Pancreatic ductal adenocarcinoma FOLFIRINOX Disease Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Pancreatic cancer Internal medicine medicine Humans Neoplasm Metastasis Survival rate Performance status business.industry Disease Management Metastatic Pancreatic Adenocarcinoma medicine.disease Combined Modality Therapy digestive system diseases Gemcitabine Pancreatic Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Surgery business medicine.drug |
| Zdroj: | The Surgical clinics of North America. 96(6) |
| ISSN: | 1558-3171 |
| Popis: | Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and clinically challenging malignancies to treat, with an estimated 5-year survival rate of approximately 7%. At the time of initial presentation, a majority of patients have metastatic disease. The median overall survival in these patients with good performance status is 8.5 to 11.1 months and in patients with significantly impaired performance status, even less. Strategies to integrate novel agents with traditional cytotoxic therapies are under investigation and hold promise for improving outcomes in patients with metastatic PDAC. This article focuses on the current management options and novel therapeutics for metastatic PDAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|